Literatuur ranges en indicaties

Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists. Chest 2008;133:160S-198S.

Orde van Medisch Specialisten, Nederlands Huisartsengenootschap, Kwaliteitsinstituut CBO. Richtlijn diagnostiek, preventie en behandeling van veneuze trombo-embolie en secundaire preventie arteriële trombose. CBO-richtlijn 2008.

Rosendaal FR, Cannegieter SC, van der Meer FJM, Briët E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993;39:236-239.

Van Geest-Daalderop JHH, Augueste Sturk A, Levi M, Adriaansen HJ. Omvang en kwaliteit van de antistollingsbehandeling met cumarinederivaten door de Nederlandse trombosediensten. Ned Tijdschr Geneesk 2004; 148:730-735.

Veeger NJGM, Piersma-Wichers M, Tijssen JGP, Hillige HL, van der Meer J. Individual time within target range in patients treated with vitamin K antagonists: main determinant of quality of anticoagulation and predictor of clinical outcome. A retrospective study of 2300 consecutive patients with venous thromboembolism. Br J Haematol 2005;128:513-9.

Torn M, Bollen ELEM, Van der Meer FJM, Tanis BC, Van der Wall EE, Rosendaal FR. Optimal level of oral anticoagulant therapy for the prevention of arterial thrombosis in patients with mechanical heart valve prostheses, atrial fibrillation or myocardial infarction: a prospective study of 4202 patients. Arch Intern Med 2009;169:1203-1209.

Federatie van Nederlandse Trombosediensten. Vademecum voor poliklinische antistollingsbehandeling met cumarinederivaten 2005. www.fnt.nl.

Dunning J, Versteegh M, Fabbri A, Pavie A, Kohl P, Lockowandt U, Nashef S, Guideline on antiplatelet and anticoagulation management in cardiac surgery. European Journal of Cardio-thoracic Surgery 2008;34:73-92.

Salem DN, O’Gara PT, Madias C, Pauker SG. Valvular and structural heart disease. Chest 2008;133:593S-629S.

Vink R, van den Brink RBA, Levi M. Antistollingsbehandeling bij patiënten met boezemfibrilleren: afhankelijk van leeftijd en andere risicofactoren voor trombo-embolie. Ned Tijdschr Geneeskd 2002;146:2285-2289.

Singer D, Albers GW, Dalen J, Fang MC, Go AS, Halperin JL, Lip GYH, Manning WJ. Antithrombotic therapy in atrial fibrillation. Chest 2008;133:546S-592S.

Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994;154:1449-1457.

Hylek EM, Go AS, Chang Y, Jensvold NG, Henault LE, Selby JV, Singer DE. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003;349:1019-1026.

Salem DN, O’Gara PT, Madias C, Pauker SG. Valvular and structural heart disease. Chest 2008;133:593S-629S.

Cannegieter SC, Rosendaal FR, Wintzen AR, van der Meer FJM, Vandenbroucke JP, Briët E. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 1995;333:11-17.

Vink R, Kraaijenhagen RA, Hutten BA, van den Brink RB, de Mol BA, Büller HR, Levi M. The optimal intensity of vitamin K antagonists in patients with mechanical heart valves: a meta-analysis. J Am Coll Cardiol 2003; 42:2042-2048.

Heit JA. The epidemiology of venous thromboembolism in the community: Implications for prevention and management. J Thromb Thrombolysis 2006;21:23-29.

Levi M. Microalbuminurie is (een beetje) een risicofactor voor veneuze trombose. Ned Tijdschr Geneeskd 2009;153:1736.

Kwaliteitsinstituut voor de gezondheidszorg CBO. Richtlijn diep veneuze trombose en longembolie 1999.

Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ. Antithrombotic therapy for venous thromboembolic disease. Chest 2008;133:454S-545S.

Kearon C, Ginsberg JS, Kovacs MJ, Anderson DR, Wells P, Julian JA, MacKinnon B, Weitz JI, Crowther MA, Dolan S, Turpie AG, Geerts W, Solymoss S, van Nguyen P, Demers C, Kahn SR, Kassis J, Rodger M Hambleton J, Gent M. Extended low-intensity anticoagulation for thromboembolism investigators. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 2003;349:631-639.

Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama C, Lassen MR, Colwell CW. Prevention of venous thromboembolism. Chest 2008;133:381S-453S.

Van Hulst RA. Decompressieziekte, duik er eens in. NMTG 2008;61:95-99.

Rienks R. Duiken en het hart. Ned. Ver. van Duikende Cardiologie 2007. In press.

Hefti JP, Risch L, Hefti U, Scharrer I, Risch G, Merz TM, Turk A, Bosch MM, Barthelmess D, Schoch O, Maggiorini, Huber AR. Changes of coagulation parameters during high altitude expedition. Swiss Med Wkly 2009;Nov 30. In press.

Schreijer AJM, Cannegieter SC, Rosendaal FR, Helmerhorst FM. A case of thrombosis at high altitude. Thromb Haemost 2005;94:1104-1105.

Tissot van Patot MC, Hill AE, Dingmann C, Gaul L, Fralick K, Christians U, Honigman B, Salman MD. Risk of impaired coagulation in warfarin patients ascending to altitude (>2400 m). High Alt Med Biol 2006;7:39-46.

Federatie van Nederlandse Trombosediensten. Samenvatting Medisch Jaarverslagen 2008.